Kadimastem Ltd - Asset Resilience Ratio

Latest as of September 2016: 16.66%

Kadimastem Ltd (KDST) has an Asset Resilience Ratio of 16.66% as of September 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check KDST strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

ILA1.20 Million
≈ $3.22K USD Cash + Short-term Investments

Total Assets

ILA7.20 Million
≈ $19.31K USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2015)

This chart shows how Kadimastem Ltd's Asset Resilience Ratio has changed over time. See KDST equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Kadimastem Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Kadimastem Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ILA0.00 0%
Short-term Investments ILA1.20 Million 16.66%
Total Liquid Assets ILA1.20 Million 16.66%

Asset Resilience Insights

  • Good Liquidity Position: Kadimastem Ltd maintains a healthy 16.66% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Kadimastem Ltd Industry Peers by Asset Resilience Ratio

Compare Kadimastem Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 2.21%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Bachem Holding AG
SW:BANB
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
ABL Bio Inc
KQ:298380
Biotechnology 1.05%
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Biotechnology 80.13%
Ascletis Pharma Inc
F:2VJ
Biotechnology 22.13%
ABCELLERA BIOLOGICS
F:8QQ
Biotechnology 29.87%

Annual Asset Resilience Ratio for Kadimastem Ltd (2013–2015)

The table below shows the annual Asset Resilience Ratio data for Kadimastem Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2015-12-31 31.57% ILA2.50 Million
≈ $6.70K
ILA7.92 Million
≈ $21.23K
-24.87pp
2014-12-31 56.45% ILA6.79 Million
≈ $18.20K
ILA12.02 Million
≈ $32.24K
+0.90pp
2013-12-31 55.55% ILA6.89 Million
≈ $18.48K
ILA12.41 Million
≈ $33.27K
--
pp = percentage points

About Kadimastem Ltd

TA:KDST Israel Biotechnology
Market Cap
$22.18 Million
ILA8.27 Billion ILA
Market Cap Rank
#24751 Global
#359 in Israel
Share Price
ILA2794.00
Change (1 day)
-1.13%
52-Week Range
ILA2321.00 - ILA3680.00
All Time High
ILA78228.15
About

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more